Egalet Corporation (NASDAQ:EGLT) currently has a “Hold” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
Egalet Corporation (NASDAQ:EGLT) lost -4.64 Percent and closed its previous trading session at $0.84. The stock traded with the average Volume of 1.49 Million at the end of last session.
Egalet Corporation (NASDAQ:EGLT) has the Market Capitalization of 37.49 Million. The Stock has its 52-week High of $5.600 and 52-Week Low of $0.670 and it touched its 52-week high on 03/29/17 and 52-Week Low on 02/23/18.
The company reported its last earnings Actual EPS of $-0.46/share. While, the analyst predicted that the company could provide an EPS of $-0.45/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.01/share which shows an Earnings Surprise of -2.2 Percent.
Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Egalet Corporation (NASDAQ:EGLT) as Buy, 0 analysts given Outperform signal, 1 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 9.13% where SMA50 and SMA200 are -6.16% and -35.27% respectively.
The company shows its Return on Assets (ROA) value of -73.8%. The Return on Equity (ROE) value stands at 421.7%. While it’s Return on Investment (ROI) value is -89.4%.
Egalet Corporation (NASDAQ:EGLT) currently has a Weekly Volatility of 12.20% percent while its Monthly Volatility is at 8.59% percent. While talking about Performance of the Stock, Egalet Corporation currently has a Weekly performance of 10.71%, monthly performance percentage is 2.65 percent, Quarterly performance is -19.31 percent, 6 months performance shows a percent value of -38.74% and Yearly Performance is -82.14 percent.
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in the developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications. Its principal product candidate consist of Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain and Egalet-003 which are in pre-clinical trials. Egalet Corporation is based in City of Westminster, United Kingdom.